• Contact Us
  • Careers
  • Facebook (opens in a new tab)
  • Instagram (opens in a new tab)
  • LinkedIn (opens in a new tab)
  • Twitter (opens in a new tab)
  • YouTube (opens in a new tab)
Travere Therapeutics
  • Our Company
    • Who We Are
    • Leadership & Board
    • Patient Advocacy
    • Our Culture in Action
    • Grant Programs
      • Advocacy & Charitable Grants
      • ISR Grants
      • Med Ed Grants
    • Contact Us
    • Careers
    • Company News
  • Our Science
    • Our Pipeline
      • Pegtibatinase
      • Civorebrutinib
    • Therapeutic Areas
      • IgA Nephropathy (IgAN)
      • Focal Segmental Glomerulosclerosis (FSGS)
      • Classical Homocystinuria (HCU)
      • Cystinuria
    • Clinical Trials
    • Expanded Access
    • Publications
    • Medical Affairs
  • Our Therapies
  • Rare Life
  • Investors & Media
  • Home
  • ▶
  • Travere Therapeutics to Participate at Upcoming Investor Conferences
  • ▶

Travere Therapeutics to Participate at Upcoming Investor Conferences

View Full Press Release
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Travere Therapeutics Announces Full FDA Approval of FILSPARI® (sparsentan), the First and Only Approved Medicine for FSGS
↑ Return to Top
Travere logo
  • Facebook (opens in a new tab)
  • Instagram (opens in a new tab)
  • LinkedIn (opens in a new tab)
  • Twitter (opens in a new tab)
  • YouTube (opens in a new tab)
  • Terms & Conditions
  • Privacy
  • Your Privacy Choices

© 2026 Travere Therapeutics, Inc. All rights reserved. For U.S. audiences. Total Care Hub®, Travere TotalCare®, and Filspari® are registered trademarks of Travere Therapeutics.  Thiola® and Thiola EC® are registered trademarks of Mission Pharmacal Company.